Vestipitant

Vestipitant
	220px
Systematic (IUPAC) name
	(2S)-N-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-2-(4-fluoro-2-methylphenyl)-N-methylpiperazine-1-carboxamide
Identifiers
CAS Number	334476-64-1
ATC code	none
PubChem	CID 9832383
Chemical data
Formula	C23H21F10N3O
Molar mass	545.416 g/mol[[Script error: No such module "String".]]
	Script error: No such module "collapsible list".

Script error: No such module "TemplatePar".Expression error: Unexpected < operator.

Vestipitant is a drug developed by GlaxoSmithKline which acts as a selective antagonist for the NK₁ receptor. It is under development as a potential antiemetic and anxiolytic drug,^[1]^[2] and as a treatment for tinnitus.^[3]

References

Cite error: Invalid <references> tag; parameter "group" is allowed only.

Use <references />, or <references group="..." />

45px	This drug article relating to the gastrointestinal system is a stub. You can help ssf by expanding it. v d e

35px	This drug article relating to the nervous system is a stub. You can help ssf by expanding it. v d e

↑ Reddy GK, Gralla RJ, Hesketh PJ. Novel neurokinin-1 antagonists as antiemetics for the treatment of chemotherapy-induced emesis. Supportive Cancer Therapy. 2006 Apr 1;3(3):140-2. PMID 18632487
↑ Brocco M, Dekeyne A, Mannoury la Cour C, Touzard M, Girardon S, Veiga S, de Nanteuil G, deJong TR, Olivier B, Millan MJ. Cellular and behavioural profile of the novel, selective neurokinin1 receptor antagonist, vestipitant: a comparison to other agents. European Neuropsychopharmacology. 2008 Oct;18(10):729-50. PMID 18657401
↑ ClinicalTrials.gov NCT00394056 Vestipitant Or Vestipitant/Paroxetine Combination In Subjects With Tinnitus And Hearing Loss